Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Bladder Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


9 drugs have received FDA approval for Bladder Cancer . Atezolizumab, Avelumab, Cisplatin, Doxorubicin Hydrochloride, Durvalumab, Mesna, Nivolumab, Pembrolizumab and Thiotepa
164 drugs have a clinical trial registered for Bladder Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 741 clinical trials for Bladder Cancer,
440 of which have one or more drug interventions,
301 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 241 Cell Line Models for Bladder Cancer.

Source: COSMIC
(see details)

Chemistry


There are 598 Compounds which have been tested in Bladder Cancer , 410 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Bladder Cancer:
Ureteral Neoplasms
Urethral Neoplasms
Urinary Bladder Neoplasms
Urologic Neoplasms

The following terms have been mapped from cancer.gov to Bladder Cancer:
Bladder cancer
Bladder cancer that cannot be treated with surgery or radiation therapy
Hemorrhagic cystitis (bleeding in the bladder) caused by chemotherapy with ifosfamide
Transitional cell bladder cancer
Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease got worse during or after treatment with platinum chemotherapy
Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized. It is used in:Patients whose cancer has the PD-L1 protein and cannot be treated with cisplatin
Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized. It is used in patients whose disease got worse during or after treatment with platinum chemotherapy
Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized. It is used in patients whose disease got worse during or after treatment with platinum chemotherapy
Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized. It is used in:Adults whose cancer has the PD-L1 protein and cannot be treated with cisplatin.????